Investigators flouting device trials rules subject to greater FDA scrutiny
This article was originally published in Clinica
Executive Summary
The US FDA has stepped up its efforts to prevent trial investigators who have already been debarred or disqualified by the agency from taking part in further clinical studies during their disqualification period.
You may also be interested in...
US: The sun shines in on industry-doctor relationships
The US healthcare reform proposals signed into law on 23 March include requirements on medical device companies to reveal payments or gifts they make to doctors. Peter Rixon takes a closer look at what the reforms’ “sunshine” provisions actually mean
Global regulators/industry to gather in US and Germany to talk device regulation
Compliance, approvals, inspections and many other burning issues will be on the agenda of a US conference that takes place in the coming weeks.
Global regulators and industry execs to gather in US and Germany to talk device regulation
Compliance, approvals, inspections and many other burning issues will be on the agenda of a US conference that takes place in early May.